Nemolizumab Plus Topical Agents Improve Atopic Dermatitis and Moderate to Severe Pruritus up to 68 Weeks
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies
Br J Dermatol 2021 Nov 02;[EPub Ahead of Print], K Kabashima, T Matsumura, H Komazaki, M KawashimaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.